Equity Research firms currently have a positive stance on shares of vTv Therapeutics Inc. (NASDAQ:VTVT). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.40. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $18.00 on a short term basis.
At the time of writing, the stock was trading at $6.62. This represents a change from the opening price of -1.19%. In terms of performance, year to date, the stock is -2.20%. The monthly stock performance comes in at 13.27%. For the quarter, shares are performing at 11.37%. Weekly performance analysis shows the equity at -6.85%.
In taking a look at technical levels, shares are trading 7.06% away from the 50 day simple moving average and 9.45% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -19.46% away from it’s 52- week high and 36.78% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, vTv Therapeutics Inc.’s RSI stands at 47.12. In looking at volatility levels, the shares saw weekly volatility of 4.68% and 4.56% over the past month.